SACT time to first treatment dashboard

The Systemic Anti-Cancer Therapy (SACT) time to first treatment (TTFT) dashboard reports the time taken for patients to be treated with SACT drugs once they have been approved by the National Institute of Health and Care Excellence (NICE) for routine commissioning in the NHS.  The dashboard includes SACT drugs in Section B of the NICE CDF list (NICE & NHS England approved cancer drugs/indications routinely funded by NHS England from 1 April 2016, including CDF and non-CDF approved drugs). All treatments with a publication date prior to 1 January 2019 have been excluded from analysis. The dashboard uses SACT data submitted by NHS trusts and provides time to treatment for each trust and cancer alliance, alongside a summary measure for England displaying the interquartile range (including mean and median averages).  Available filter selections include trust and cancer alliance of interest; drug and/or cancer type; alongside filtering for drugs previously available through the Cancer Drugs Fund (CDF) or the early access to medicines scheme (EAMS).

The analysis presented in this dashboard uses routine data reported by NHS Trusts in England through their monthly routine SACT data uploads.

Acknowledgement

This work uses data that has been provided by patients and collected by the NHS as part of their care and support. The data are collated, maintained and quality assured by the National Disease Registration Service (NDRS), which is part of NHS England.

Providing information on the equity of access of new SACT drugs is imperative to gain a greater understanding of the care delivered throughout the NHS.  This dashboard aims to improve cancer outcomes for patients - through identifying variation in uptake to support the understanding, and then improvement, in equitable access of new SACT drugs across the country.

The SACT data set is a population-based resource of SACT activity reported routinely by NHS Trusts in England. Data are collected on the SACT treatments of adult and paediatric patients, delivered in secondary and tertiary settings with the intention of improving survival, delaying further cancer progression or development, and improving disease-free or progression-free survival.

For more information on the SACT data set, please see the Data Resource Profile on the Oxford Academic website.

SACT start date of regimen activity from January 2019 are included in this report.

Find out more about the SACT data set.

The NICE CDF list Section B will be reviewed on an annual basis. Any new SACT drugs brought into routine commissioning under Section B (NICE & NHS England approved cancer drugs/indications routinely funded by NHS England from 1 April 2016, including CDF and non-CDF approved drugs) will be reviewed. All treatments with a publication date prior to 1 January 2019 have been excluded from analysis.

The tool is produced by the National Disease Registration Service (NDRS). Please send any feedback or queries to [email protected]

Please do not include sensitive or patient identifiable information.